Literature DB >> 12432255

Downregulation of c-FLIP sensitizes DU145 prostate cancer cells to Fas-mediated apoptosis.

Marc L Hyer1, Sunil Sudarshan, Youngsoo Kim, John C Reed, Jian-yun Dong, David A Schwartz, James S Norris.   

Abstract

Although DU145 prostate cancer cells are resistant to exogenously applied Fas agonist CH-11 (anti-Fas monoclonal antibody), Fas-resistance can be overcome using a FasL expressing adenovirus (AdGFPFasL(TET)) [Hyer et al., Molecular Therapy, 2000; 2:348-58 (ref.12)]. The purpose of this study was to try to understand why DU145 cells are resistant to CH-11 and determine the signaling pathway utilized by AdGFPFasL(TET) to induce apoptosis in these Fas-resistant cells. Using immunoblot analysis, we show that AdGFPFasL(TET) is capable of initiating the classic Fas-mediated apoptotic pathway in DU145 cells, which includes activation of caspases-8, -3, -7, and -9, BID cleavage, cytochrome c release from mitochondria, and PARP cleavage. In contrast, CH-11 binds to Fas, but is unable to transmit the death signal beyond the plasma membrane suggesting a block at the DISC (death inducing signaling complex). The anti-apoptotic protein c-FLIP (cellular Flice-like inhibitory protein), which has been shown to inhibit Fas-mediated apoptosis at the DISC, was down-regulated following AdGFPFasL(TET) treatment prompting us to investigate its role in inhibiting CH-11-induced cell death. Using c-FLIP anti-sense oligonucleotides to down-regulate c-FLIP we sensitized DU145 cells to CH-11-induced apoptosis. These data suggest that c-FLIP may play a critical role in regulating Fas-mediated apoptosis in prostate cancer cells and that modulation of c-FLIP may enhance Fas signaling based therapies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12432255     DOI: 10.4161/cbt.1.4.15

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  12 in total

Review 1.  Apoptosis evasion: the role of survival pathways in prostate cancer progression and therapeutic resistance.

Authors:  Shaun McKenzie; Natasha Kyprianou
Journal:  J Cell Biochem       Date:  2006-01-01       Impact factor: 4.429

2.  The androgen receptor directly targets the cellular Fas/FasL-associated death domain protein-like inhibitory protein gene to promote the androgen-independent growth of prostate cancer cells.

Authors:  Shen Gao; Peng Lee; Hua Wang; William Gerald; Michael Adler; Liying Zhang; Yun-Fang Wang; Zhengxin Wang
Journal:  Mol Endocrinol       Date:  2005-02-24

3.  PKCdelta-mediated regulation of FLIP expression in human colon cancer cells.

Authors:  Qingding Wang; Xiaofu Wang; Yuning Zhou; B Mark Evers
Journal:  Int J Cancer       Date:  2006-01-15       Impact factor: 7.396

4.  Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells.

Authors:  Andrew M Roberts; Ian R Watson; Andrew J Evans; David A Foster; Meredith S Irwin; Michael Ohh
Journal:  Cancer Res       Date:  2009-11-17       Impact factor: 12.701

Review 5.  Cellular FLICE-inhibitory protein: an attractive therapeutic target?

Authors:  Olivier Micheau
Journal:  Expert Opin Ther Targets       Date:  2003-08       Impact factor: 6.902

6.  Combined treatment with denbinobin and Fas ligand has a synergistic cytotoxic effect in human pancreatic adenocarcinoma BxPC-3 cells.

Authors:  C R Yang; J H Guh; C M Teng; C C Chen; P H Chen
Journal:  Br J Pharmacol       Date:  2009-05-18       Impact factor: 8.739

Review 7.  Apoptosis: targets in pancreatic cancer.

Authors:  Sabine Westphal; Holger Kalthoff
Journal:  Mol Cancer       Date:  2003-01-07       Impact factor: 27.401

8.  Embelin downregulated cFLIP in breast cancer cell lines facilitate anti-tumor effect of IL-1β-stimulated human umbilical cord mesenchymal stem cells.

Authors:  Ya-Han Liang; Jiann-Ming Wu; Jui-Wen Teng; Eric Hung; Hwai-Shi Wang
Journal:  Sci Rep       Date:  2021-07-19       Impact factor: 4.379

9.  Enhancement of the activity of phenoxodiol by cisplatin in prostate cancer cells.

Authors:  R A C McPherson; P T Galettis; P L de Souza
Journal:  Br J Cancer       Date:  2009-02-10       Impact factor: 7.640

10.  Expression and biological significance of c-FLIP in human hepatocellular carcinomas.

Authors:  Xilin Du; Guoqiang Bao; Xianli He; Huadong Zhao; Fang Yu; Qing Qiao; Jianguo Lu; Qingjiu Ma
Journal:  J Exp Clin Cancer Res       Date:  2009-02-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.